Early-stage lung adenocarcinoma alters DNA methylation, mRNA transcription, and protein expression in adjacent tissues, exhibiting either steep changes at the tumor boundaries or shallow changes ...

Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...

Return on Assets (ROA): Stoke Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.93%, the company may encounter challenges ...

This important study examines the potential role of ARHGAP36 transcriptional regulation by FOXC1 in controlling sonic hedgehog signaling in human neuroblastoma. While there are many solid findings ...

All data from 1,100+ Answer ALS participants, including ALS TDI's ARC study data, are now harmonized and accessible via the Neuromine Data Portal, forming the world's largest open ALS research ...

The partnership will accelerate efficient and sustainable manufacturing of high-demand proteins and peptides, such as GLP-1 analogs, for pharmaceutical and biotechnology clients TOKYO ...

A research team led by Prof. Hou Xingliang from the South China Botanical Garden of the Chinese Academy of Sciences has used ...

Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...

Acute myeloid leukemia driven by tandem duplications within the UBTF gene (UBTF-TD AML) is a high-risk pediatric cancer in ...

Protalix ( ($PLX) ) has issued an update. On November 3, 2025, Protalix BioTherapeutics and Chiesi Global Rare Diseases announced their request ...

Creative BioMart offers a vast array of supplementary products in addition to full length proteins, such as native proteins, recombinant protein fragments, GMP-grade proteins, labeled proteins ...